The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome

Treatment with empagliflozin, an inhibitor of the sodium/glucose cotransporter 2 (SGLT2), is associated with slower progression of diabetic kidney disease. In this analysis, we explored the hypothesis that empagliflozin may have an impact on urinary peptides associated with chronic kidney disease (C...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:PLoS One
Asıl Yazarlar: Cherney, David, Perkins, Bruce A., Lytvyn, Yuliya, Heerspink, Hiddo, Rodríguez-Ortiz, María E., Mischak, Harald
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Public Library of Science 2017
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5662219/
https://ncbi.nlm.nih.gov/pubmed/29084249
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0186910
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller